Abstract: Compounds, compositions and methods are provided for inhibiting the expression of human STAT3. The compositions comprise antisense oligonucleotides targeted to nucleic acids encoding STAT3. Methods of using these oligonucleotides for inhibition of STAT3 expression and for treatment of diseases, particularly inflammatory diseases and cancers, associated with overexpression or constitutive activation of STAT3 are provided.
Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of Smad7. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Smad7. Methods of using these compounds for modulation of Smad7 expression and for treatment of diseases associated with expression of Smad7 are provided.
Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of Peroxisome proliferator-activated receptor gamma. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Peroxisome proliferator-activated receptor gamma. Methods of using these compounds for modulation of Peroxisome proliferator-activated receptor gamma expression and for treatment of diseases associated with expression of Peroxisome proliferator-activated receptor gamma are provided.
Type:
Grant
Filed:
January 18, 2000
Date of Patent:
December 12, 2000
Assignee:
Isis Pharmaceuticals, Inc.
Inventors:
Robert McKay, Alexander H. Borchers, Brenda F. Baker
Abstract: Active ingredient-containing layered articles or discs which are suitable, in particular, as active ingredient reservoirs for transdermal therapeutic systems are obtained starting from an elongate article having an enveloping surface corresponding to the contour of the layered articles to be produced, and having a cross-sectional constitution corresponding to the internal structure of the layered articles, by layered detachment perpendicular to the axial direction of the elongate article. In the simplest case, this article consists of a uniform active ingredient-containing composition and forms a solid cylinder which is converted into single products perpendicular to the axis with identical spacing to result in circular one-compartment discs identical to one another.
Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of SRC-3. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding SRC-3. Methods of using these compounds for modulation of SRC-3 expression and for treatment of diseases associated with expression of SRC-3 are provided.
Abstract: This invention concerns compositions and methods for the treatment of CMV infections. Antisense oligonucleotides are provided which are effective antiviral agents. In preferred embodiments, the oligonucleotides contain at least one 2'-methoxyethoxy modification and may be chimeric oligonucleotides.
Type:
Grant
Filed:
April 9, 1997
Date of Patent:
November 28, 2000
Assignee:
Isis Pharmaceuticals Inc.
Inventors:
Kenneth G. Draper, Daniel L. Kisner, Kevin P. Anderson, Sharon Chapman
Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of CD44. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding CD44. Methods of using these compounds for modulation of CD44 expression and for treatment of diseases associated with expression of CD44 are provided.
Abstract: A cell culture vessel formed generally about an elongate axis and being provided with a neck and a removable closure member, and at a distal end thereof an end closure portion; said vessel being adapted for tissue culture growth and formed of a sterilizable plastics material, wherein the internal surface of the vessel is wettable for the attachment of cells; said vessel being characterized in that its cross-section in a direction perpendicular to said elongate axis is non-cylindrical whereby it cannot rotate smoothly by rolling on its surface(s).
Abstract: A station for sorting solid waste is provided with at least one transportation belt located outside of a waste loading and unloading zone and situated in a room of a superstructure mounted on a platform, an impervious housing inside the superstructure with at least one pair of openings and a control window, a pair of sleeves ending in gloves which seal the openings of the impervious housing and fit the arms and hands of a person doing the waste sorting, and dumping points inside the impervious housing which are allocated to one sorting person and are arranged on both sides of the transportation belt.
Abstract: A patch test plaster having at least one active substance receptacle arranged on a backing film, having a highly elastic backing film which is made of polymeric material, is impermeable to liquid water but permeable to water vapour, and is releasibly connected on the surface facing away from the skin to a supporting sheet and is provided on the surface facing the skin with an adhesive layer which is in turn covered by an at least two-part detachable protecting layer before application of the plaster, is characterized in that the protecting layer has a hinge-like connection on two opposite edges to the supporting sheet.
Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of Y-box binding protein 1. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Y-box binding protein 1. Methods of using these compounds for modulation of Y-box binding protein 1 expression and for treatment of diseases associated with expression of Y-box binding protein 1 are provided.
Abstract: Compositions and methods for the treatment and diagnosis of diseases or conditions amenable to treatment through modulation of expression of a gene encoding a p38 mitogen-activated protein kinase (p38 MAPK) are provided. Methods for the treatment and diagnosis of diseases or conditions associated with aberrant expression of one or more p38 MAPKs are also provided.
Type:
Grant
Filed:
April 6, 1999
Date of Patent:
October 31, 2000
Assignee:
Isis Pharmaceuticals Inc.
Inventors:
Brett P. Monia, William A. Gaarde, Pamela S. Nero, Robert McKay
Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of bc1-6. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding bc1-6. Methods of using these compounds for modulation of bc1-6 expression and for treatment of diseases associated with expression of bc1-6 are provided.
Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of methionine aminopeptidase 2. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding methionine aminopeptidase 2. Methods of using these compounds for modulation of methionine aminopeptidase 2 expression and for treatment of diseases associated with expression of methionine aminopeptidase 2 are provided.
Abstract: Compositions and methods are provided for antisense modulation of interleukin-5 signal transduction. Antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding interleukin-5 and interleukin-5 receptor.alpha. are preferred. Methods of using these compounds for modulation of interleukin-5 signal transduction and for treatment of diseases associated with interleukin-5 signal transduction are also provided.
Type:
Grant
Filed:
March 26, 1999
Date of Patent:
October 24, 2000
Assignee:
Isis Pharmaceuticals Inc.
Inventors:
Nicholas M. Dean, James G. Karras, Robert McKay
Abstract: Methods for preventing or treating vascular hemorrhaging such as that incident to thrombolytic therapy, or characteristic of Alzheimer's and related diseases are provided. Such methods provide improved thrombolytic therapy to individuals who receive such therapy, and permit the diagnosis and treatment of diseases, such as Alzheimer's Disease, that are characterized by the deposition of amyloid deposits.
Type:
Grant
Filed:
September 2, 1999
Date of Patent:
October 24, 2000
Assignee:
Rutgers, The State University of New Jersey
Abstract: Compounds, compositions and methods are provided for inhibiting FAK mediated signaling. The compositions comprise antisense compounds targeted to nucleic acids encoding FAK. Methods of using these antisense compounds for inhibition of FAK expression and for treatment of diseases, particularly cancers, associated with overexpression or constitutive activation of FAK are provided.
Abstract: Compositions and methods for the treatment and diagnosis of diseases or disorders amenable to treatment through modulation of expression of a gene encoding a Jun N-terminal kinase (JNK protein) are provided. Oligonucleotide are herein provided which are specifically hybridizable with nucleic acids encoding JNK1, JNK2 and JNK3, as well as other JNK proteins and specific isoforms thereof. Methods of treating animals suffering from diseases or disorders amenable to therapeutic intervention by modulating the expression of one or more JNK proteins with such oligonucleotide are also provided. Methods for the treatment and diagnosis of diseases or disorders associated with aberrant expression of one or more JNK proteins are also provided. Methods for inducing apoptosis and for treating diseases or conditions associated with a reduction in apoptosis are also provided.
Type:
Grant
Filed:
April 7, 1999
Date of Patent:
October 17, 2000
Assignee:
Isis Pharmaceuticals Inc.
Inventors:
Robert McKay, Nicholas Dean, Brett P. Monia, Pamela S. Nero, William A. Gaarde
Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of PI3 kinase p110 beta. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding PI3 kinase p110 beta. Methods of using these compounds for modulation of PI3 kinase p110 beta expression and for treatment of diseases associated with expression of PI3 kinase p110 beta are provided.
Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of Telomeric Repeat Binding Factor 1. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Telomeric Repeat Binding Factor 1. Methods of using these compounds for modulation of Telomeric Repeat Binding Factor 1 expression and for treatment of diseases associated with expression of Telomeric Repeat Binding Factor 1 are provided.